(Q44130825)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180114%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

title

Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180114%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

main subject

phase II clinical trial

0 references

author

Sun Young Rha

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180114%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

author name string

Y Koh

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180114%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

H Y Lim

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180114%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

J H Ahn

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180114%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

J-L Lee

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180114%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Y J Kim

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180114%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

T M Kim

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180114%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

S-H Lee

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180114%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

publication date

23 November 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180114%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180114%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180114%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180114%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

page(s)

1026-1031

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180114%20AND%20SRC:MED&resulttype=core&format=json

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

18 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS582

2004 WHO classification of the renal tumors of the adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS582

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS582

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS582

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS582

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS582

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS582

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS582

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS582

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS582

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS582

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS582

Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS582

Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS582

Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS582

Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS582

Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS582

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS582

Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS582

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDS582

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180114%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference